Last updated: June 15, 2026
Emtricitabine and Tenofovir Disoproxil Fumarate Suppliers: API, Intermediates, and Finished-Dose Manufacturers (Global)
Executive summary: Suppliers span (1) emtricitabine (FTC) API and tenofovir disoproxil fumarate (TDF) API producers, (2) contract manufacturers for solid oral dosage (tablets/capsules), and (3) logistics and packaging vendors used for finished-dose distribution. The market is fragmented across China and India for APIs and globally for finished-dose manufacturing.
Who supplies emtricitabine and tenofovir disoproxil fumarate (TDF/FTC) APIs?
Answer (API supply): The supply chain is dominated by contract and integrated API manufacturers in China and India, with a smaller subset of Western/North Asian specialty producers supplying finished products or high-confidence commercial lots.
Which companies make emtricitabine (FTC) API
Common supplier profiles fall into:
- Generic API producers (bulk FTC manufacture, routine regulatory support)
- Niche producers (limited capacity, higher quality systems, fewer SKUs)
Typical documentation packages for FTC include DMF support or supplier letters of authorization for drug master file cross-references.
Which companies make tenofovir disoproxil fumarate (TDF) API
TDF API supply also clusters in:
- High-volume generic API manufacturers
- Process-development focused API makers supporting scale-up for tablet programs
TDF manufacturing requires tight control of impurities and salt form specifications tied to regulatory filings.
What API forms and specs do suppliers typically provide
- FTC: drug substance for solid oral formulations, with impurity reporting aligned to regulatory limits
- TDF: drug substance including fumarate salt form confirmation, impurity profiles, and polymorph-related controls where applicable
Which contract manufacturers produce TDF/FTC tablets for global brands and generics?
Answer (finished-dose supply): Contract manufacturing organizations (CMOs) in India, China, and Europe produce fixed-dose combination tablets using:
- Direct compression or granulation depending on tablet strength and excipient system
- Tight in-process controls for dissolution and impurity formation
What dosage forms are typically manufactured
- Film-coated tablets (dominant commercial form)
- Occasional alternative solid oral forms depending on market and dose strength
How formulation choices affect supplier selection
Key differentiators CMOs compete on:
- Dissolution profile consistency for generic approval
- Impurity control during compression/granulation
- Stability under accelerated and long-term conditions for FTC + TDF combination
Do suppliers differ by dosage strength (200 mg FTC / 300 mg TDF)?
Answer (strength-specific sourcing): Yes. While the API supply is shared across programs, commercial tablet programs are strength- and excipient-system specific. Suppliers that can reliably match:
- Tablet weight
- Coating system
- Dissolution target
- Stability behavior
tend to win repeat awards across markets.
What patents or exclusivity constrain supplier transitions for FTC/TDF?
Answer (IP constraint): For supplier selection, the practical constraint is often not “raw material availability” but regulatory and litigation posture tied to specific reference products and combination tablets. Patent estates can affect whether a generic can launch with certain processes, formulations, or method-of-use claims.
How IP status impacts sourcing
- If a specific combination strength is protected, CMOs still produce drug substance but sponsors face launch restrictions.
- Where formulation or process patents exist, CMOs must align with non-infringing process routes and impurity specs.
Which generic entry risks impact FTC/TDF supplier readiness?
Answer (generic entry risks): The main risks are regulatory rather than technical:
- FDA or EMA approval pathway delays due to dissolution/impurity discrepancies
- Stability-related changes requiring reformulation
- Litigation stay risks where Paragraph IV challenges or follow-on patent claims exist
These issues slow down supplier qualification timelines even when API supply is available.
What is the Orange Book status for FTC/TDF fixed-dose combinations?
Answer (Orange Book status): Orange Book status is product-specific and varies by strength and sponsor. The Orange Book listing determines:
- Whether there are unexpired drug product patents and use patents
- Whether a biosimilar-style concept applies (it does not for small molecules)
- Whether generics can file Paragraph IV certifications
Which FDA regulatory pathways do FTC/TDF tablet sponsors use?
Answer (pathways): Generic sponsors generally pursue:
- ANDA with bioequivalence and chemistry/manufacturing controls
- Section 505(b)(2) in some scenarios when bridging is required to a listed drug’s data package
Supplier qualification must support dossier creation, including:
- Batch manufacturing records
- Release testing methods
- Stability protocols
- Validation packages
Which markets have the tightest supplier concentration for FTC/TDF?
Answer (market concentration): Supply concentration is usually highest where:
- Brand competition is low
- Tendering is fragmented but supplier qualification is strict
- Local manufacturing requirements exist (regional registration and GMP presence)
Historically, high-volume tender markets often see the most bids from Asian API/solid oral CMOs.
How do suppliers support quality systems for FTC/TDF manufacture?
Answer (quality systems): Sponsors assess suppliers on:
- GMP compliance track record across jurisdictions
- Ability to provide COAs, traceability, and impurity method validation
- Stability and forced degradation documentation to support regulatory submissions
Supplier landscape: what to expect by role in the supply chain
Role 1: API manufacturers
Deliver:
- Drug substance COAs and specs
- DMF or other regulatory referencing support
- Process impurity control packages
Role 2: Intermediate manufacturers
Deliver:
- Key intermediates used to build FTC or TDF
- Route-specific impurity control to avoid downstream deviation
Role 3: CMOs for tablets
Deliver:
- Dosage form engineering and scale-up
- Validation for blending, granulation, compression, and coating
- Stability program execution
Role 4: Packaging and distribution
Deliver:
- Blistering and bottle packaging validation
- Serialization/track-and-trace support where required
- Regional cold chain is typically not a defining requirement for these molecules, but distribution conditions still matter for stability
Key due-diligence checklist for selecting FTC/TDF suppliers
- API control strategy: impurity profiles, residual solvents, particle size and polymorph controls as applicable
- CMC documentation readiness: batch data packages that match the intended regulatory pathway
- Tablet performance evidence: dissolution and stability alignment to target strengths
- Regulatory track record: inspection outcomes and on-time submission support
- Supply continuity: capacity planning and lead times for both APIs and packaging
Key Takeaways
- FTC/TDF supply is built on separate API and finished-dose manufacturing layers, with China and India dominating API volume and global CMOs supporting tablet production.
- Supplier qualification is driven by CMC data readiness and impurity/dissolution/stability control, not just API availability.
- Generic launch and tender awards depend on regulatory pathway execution and IP posture tied to specific branded or reference combination tablets.
FAQs
- Which companies are top suppliers of emtricitabine (FTC) API for generic tablet programs?
- What excipients and tablet manufacturing approaches are most common for FTC/TDF fixed-dose combinations?
- How do API impurity profiles of tenofovir disoproxil fumarate (TDF) affect ANDA approval outcomes?
- Are there formulation-specific patents that limit FTC/TDF generic manufacturing routes?
- What documentation do sponsors need from CMO suppliers to support FDA ANDA submissions for FTC/TDF tablets?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. ANDA Regulatory Requirements and Chemistry, Manufacturing, and Controls (CMC) Guidance Documents. U.S. Food and Drug Administration.
- EMA. Guideline on the requirements for quality documentation for generic medicines (EMA quality guidance). European Medicines Agency.
